hte to Deliver Technology and Service to Flanders Materials Centre
News Oct 07, 2005
hte Aktiengesellschaft, the high throughput experimentation company, has entered into a 3-year collaboration agreement with the Flanders Materials Centrein Belgium (Flamac). hte will deliver a series of integrated solutions for high throughput formations researchThe workflows to be created by hte will encompass sample preparation, application and characterization and will integrate proprietary innovations along with component instruments from a number of third party vendors to speed up materials research.
Critical to the successful roll-out of these workflows, hte's comprehensive suite of software technologies will provide the essential experimental design, process control, data management and data analysis capabilities for this complete research infrastructure.
Consulting, maintenance and support services provided by hte will ensure that the collaboration between both parties benefits from hte's extensive experience in integrating and operating high-throughput R & D facilities. hte and Flamac expect delivery of the first integrated research workflow to Flamac's new research centre in Ghent, Belgium, in early 2006.
"With this collaboration we see hte's expertise and validated technologies for high throughput experimentation being brought to yet another field of R & D," commented Dirk Demuth, CEO of hte, "We are delighted to have this opportunity to implement high-productivity solutions for formulations research in partnership with the Flanders Materials Centre."
"The agreement with hte is one more important step towards establishing Flamac as a provider of high-throughput services to materials companies and the materials science community", stated Luc Gellens, chairman of Flamac. "We look forward to a successful collaboration with hte."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.